Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
BioMed X
BioMed X
Activities:
Training & Education
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery
The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
ISPE announces 2024 Facility of the Year Awards category winners
The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Research & Development
BioMed X Institute and Merck begin second immunology project
Team TDA will join the three ongoing research groups sponsored by Merck, which follow four completed projects
Research & Development
BioMed X and Boehringer Ingelheim initiate brain sensor project
Two projects are already underway between the research partners, including one in immunology and one in neuroscience
Research & Development
BioMed X completes fourth oncology project with Merck
The next project team: “Synthetic Lethality in DNA Repair” (SDR) is led by Dr Özdemirhan Serçin, who was a postdoctoral researcher in the DDC teamv
Research & Development
BioMed X and Janssen R&D announce two research groups
The groups will explore research related to autoimmunity and drug delivery
Research & Development
BioMed X and Merck launch oncology research programme
The key aim of the project will be to generate a comprehensive atlas of extrachromosomal DNA in human cancer tissues
Research & Development
BioMed X and Merck extend research collaboration
The two entered a partnership in 2013 and the resulting research has led to 25 scientific publications
Research & Development
BioMed X begins research project for oral therapeutics delivery
The collaboration with Janssen Research and Development was facilitated by Johnson & Johnson Innovation
Subscribe now